Bromocriptine (mesylate) – 50 mg

Brand:
Cayman
CAS:
22260-51-1
Storage:
-20
UN-No:
Non-Hazardous - /

Bromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively).{21784} It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM).{21784,21785} Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP.{53230} Formulations containing bromocriptine have been used in the treatment of Parkinson’s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.  

 

SKU: - Category:

Description

A dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1-5 receptors, respectively); also binds to 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM); restores locomotor activity, without inducing dyskinesia, in a MPTP-induced macaque model of Parkinson’s disease at 5 mg/kg


Formal name: (5α)-2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-errgotaman-3′,6′,18-trione, monomethanesulfonate

Synonyms:  CB-154

Molecular weight: 750.7

CAS: 22260-51-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease